The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Exploring the relationship between cardiology and oncology in lung cancer
Gerard M. Walls, MB, MRCP, MSc, FRCR, Queen’s University, Belfast, UK, explains the importance of cardio-oncology in lung cancer. Optimization of baseline cardiovascular health may reduce cardiac risks post treatment. Side effects of radiotherapy include aggravation of heart failure, novel arrythmia and ischemic events. Established cardiovascular events prior to chemotherapy are vital indicators of post treatment cardiac risks. Quantitative study through echocardiograms and ejection fractions could aid in assessing the future risk of cardiac risks post radiotherapy. Retrospective data explores how the heart can be assessed at baseline in patients who are undergoing radiotherapy for lung cancer is currently in the process of being published. New guidelines from the European Society of Cardiology (ESC) for cardio-oncology can assist in the structure of future studies to enhance cardiovascular outcomes for patients. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
